Modified and stabilized GDF propeptides and uses thereof

• US 8,710,025 B2
• Filed: 06/14/2012
• Issued: 04/29/2014
• Est. Priority Date: 02/08/2001
• Status: Expired due to Fees

• Current Assignee: Wyeth LLC (Pfizer Inc.)
• Original Assignee: Wyeth LLC (Pfizer Inc.)
• Inventors: Wolfman, Neil M., Khor, Soo-Peang, Tomkinson, Kathleen N.
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US13/523,391
• Publication Number:
  US 20120252884A1
• Time in Patent Office: 684 Days
• Field of Search: None
• US Class Current: 514/44.R
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 21/06 Anabolic agents androgens A61P5/26
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

Claims

1. A nucleic acid molecule encoding a GDF-8 propeptide comprising a nucleic acid that hybridizes under stringent hybridization conditions, wherein hybridization is carried out at 65°

C. in 6×

SSC, to the complement of SEQ ID NO;

6 and encodes a propeptide that is modified at the aspartate residue corresponding to aspartate 76 of SEQ ID NO;

5, wherein the encoded propeptide inhibits at least one GDF-8 biological activity.

2. The nucleic acid molecule of claim 1, wherein the nucleic acid encodes an alanine residue at the position corresponding to aspartate 76 of SEQ ID NO:

5.

3. The nucleic molecule acid of claim 1 further encoding an Fc region of an IgG molecule.

4. The nucleic acid molecule of claim 3, wherein the IgG molecule is IgG1 or IgG4.

5. The nucleic acid molecule of claim 3, wherein said Fc region is at least 95% identical to the amino acid sequence of SEQ ID NO:

15 or SEQ ID NO;

16.

6. The nucleic acid molecule of claim 3, wherein said IgG Fc region is positioned carboxy-terminal to said GDF-8 propeptide.

7. The nucleic acid of claim 6 further encoding a linker peptide positioned between said GDF-8 propeptide and IgG Fc region.

8. A vector comprising the nucleic acid molecule of claim 1.

9. A host cell comprising the nucleic acid molecule of claim 1 operatively linked to a regulatory sequence.

10. The nucleic acid molecule of claim 1 further comprising a nucleic acid sequence encoding albumin.

11. The nucleic acid molecule of claim 1, wherein aspartate 76 is changed to alanine, and said nucleic acid molecule further encodes an Fc region of an IgG molecule positioned carboxy-terminal to the GDF-8 propeptide.

12. The nucleic acid molecule of claim 1, wherein said IgG molecule is an IgG1 or IgG4 molecule.

13. The nucleic acid molecule of claim 11, wherein said IgG Fc region is 95% identical to SEQ ID NO:

15 or SEQ ID NO;

16.

14. The nucleic acid molecule of claim 11, further encoding a signal sequence positioned amino-terminal to the GDF-8 propeptide.

15. The nucleic acid molecule of claim 11, further encoding a peptide linker between the GDF-8 propeptide and the IgG Fc region.

16. The nucleic acid molecule of claim 11, wherein the protein encoded by said nucleic acid molecule is at least 95% identical to the amino acid sequence of SEQ ID NO:

22.

17. A vector comprising the nucleic acid molecule of claim 11.

18. A host cell comprising the nucleic acid molecule of claim 11 operatively linked to a regulatory sequence.

19. The nucleic acid molecule of claim 11, wherein said GDF-8 propeptide is at least 240 amino acids in length.

20. The nucleic acid molecule of claim 1, wherein the GDF-8 propeptide has an increased in vivo or in vitro half life relative to a corresponding unmodified GDF-8 propeptide.